Recent advances using genetic therapies against infectious diseases and for vaccination

Anne Galy; Ben Berkhout; Karine Breckpot; Chantal Pichon; Kristie Bloom; Hans-Peter Kiem; Michael D Mühlebach; Joseph M McCune

doi:10.1089/hum.2023.123

Recent advances using genetic therapies against infectious diseases and for vaccination

Anne Galy, Ben Berkhout, Karine Breckpot, Chantal Pichon, Kristie Bloom, Hans-Peter Kiem, Michael D Mühlebach, Joseph M McCune

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

34 Downloads (Pure)

Abstract

The development of prophylatic or therapeutic medicines for infectious diseases is one of the priorities for health organizations worldwide. Innovative solutions are required to achieve effective, safe, and accessible treatments for most if not all infectious diseases, particularly those that are chronic in nature or that emerge unexpectedly over time. Genetic technologies offer versatile possibilities to design therapies against pathogens. Recent developments such as mRNA vaccines, CRISPR gene editing, and immunotherapies provide unprecedented hope to achieve significant results in the field of infectious diseases. This review will focus on advances in this domain, showcasing the cross-fertilization with other fields ( e.g., oncology), and addressing some of the logistical and economic concerns important to consider when making these advances accessible to diverse populations around the world.

Original language	English
Pages (from-to)	896-904
Number of pages	9
Journal	Human Gene Therapy
Volume	34
Issue number	17-18
Early online date	28 Aug 2023
DOIs	https://doi.org/10.1089/hum.2023.123
Publication status	Published - Sept 2023

Bibliographical note

Funding Information:
The following authors would like to acknowledge funding for this work: A.G. is funded by the french ANRS (project HIV-BVAC, 21011); C.P. is funded by Ligue Nationale Contre le Cancer (MucoRNAvac project: LNCC N° AAPARN 2021.LCC/ChP); K.Br. is funded by the EC HORIZON-HLTH-2022-DISEASE (BAXERNA project: code EUAR135); K.Bl. is supported by the South African Medical Research Council (SAMRC) through its Division of Research Capacity Development, funded by the South African National Treasury.

Publisher Copyright:
© 2023 Mary Ann Liebert, Inc.

Access to Document

10.1089/hum.2023.123Licence: Unspecified

DRAFT_review GTinfectiousdiseasesvaccines_V4Accepted author manuscript, 328 KB

Handle.net

Persistent link

Cite this

@article{3b0231439d3b446e8fdb28e53e7115bb,

title = "Recent advances using genetic therapies against infectious diseases and for vaccination",

abstract = "The development of prophylatic or therapeutic medicines for infectious diseases is one of the priorities for health organizations worldwide. Innovative solutions are required to achieve effective, safe, and accessible treatments for most if not all infectious diseases, particularly those that are chronic in nature or that emerge unexpectedly over time. Genetic technologies offer versatile possibilities to design therapies against pathogens. Recent developments such as mRNA vaccines, CRISPR gene editing, and immunotherapies provide unprecedented hope to achieve significant results in the field of infectious diseases. This review will focus on advances in this domain, showcasing the cross-fertilization with other fields ( e.g., oncology), and addressing some of the logistical and economic concerns important to consider when making these advances accessible to diverse populations around the world. ",

author = "Anne Galy and Ben Berkhout and Karine Breckpot and Chantal Pichon and Kristie Bloom and Hans-Peter Kiem and M{\"u}hlebach, {Michael D} and McCune, {Joseph M}",

note = "Funding Information: The following authors would like to acknowledge funding for this work: A.G. is funded by the french ANRS (project HIV-BVAC, 21011); C.P. is funded by Ligue Nationale Contre le Cancer (MucoRNAvac project: LNCC N° AAPARN 2021.LCC/ChP); K.Br. is funded by the EC HORIZON-HLTH-2022-DISEASE (BAXERNA project: code EUAR135); K.Bl. is supported by the South African Medical Research Council (SAMRC) through its Division of Research Capacity Development, funded by the South African National Treasury. Publisher Copyright: {\textcopyright} 2023 Mary Ann Liebert, Inc.",

year = "2023",

month = sep,

doi = "10.1089/hum.2023.123",

language = "English",

volume = "34",

pages = "896--904",

journal = "Human Gene Therapy",

issn = "1043-0342",

publisher = "Mary Ann Liebert",

number = "17-18",

}

TY - JOUR

T1 - Recent advances using genetic therapies against infectious diseases and for vaccination

AU - Galy, Anne

AU - Berkhout, Ben

AU - Breckpot, Karine

AU - Pichon, Chantal

AU - Bloom, Kristie

AU - Kiem, Hans-Peter

AU - Mühlebach, Michael D

AU - McCune, Joseph M

N1 - Funding Information: The following authors would like to acknowledge funding for this work: A.G. is funded by the french ANRS (project HIV-BVAC, 21011); C.P. is funded by Ligue Nationale Contre le Cancer (MucoRNAvac project: LNCC N° AAPARN 2021.LCC/ChP); K.Br. is funded by the EC HORIZON-HLTH-2022-DISEASE (BAXERNA project: code EUAR135); K.Bl. is supported by the South African Medical Research Council (SAMRC) through its Division of Research Capacity Development, funded by the South African National Treasury. Publisher Copyright: © 2023 Mary Ann Liebert, Inc.

PY - 2023/9

Y1 - 2023/9

N2 - The development of prophylatic or therapeutic medicines for infectious diseases is one of the priorities for health organizations worldwide. Innovative solutions are required to achieve effective, safe, and accessible treatments for most if not all infectious diseases, particularly those that are chronic in nature or that emerge unexpectedly over time. Genetic technologies offer versatile possibilities to design therapies against pathogens. Recent developments such as mRNA vaccines, CRISPR gene editing, and immunotherapies provide unprecedented hope to achieve significant results in the field of infectious diseases. This review will focus on advances in this domain, showcasing the cross-fertilization with other fields ( e.g., oncology), and addressing some of the logistical and economic concerns important to consider when making these advances accessible to diverse populations around the world.

AB - The development of prophylatic or therapeutic medicines for infectious diseases is one of the priorities for health organizations worldwide. Innovative solutions are required to achieve effective, safe, and accessible treatments for most if not all infectious diseases, particularly those that are chronic in nature or that emerge unexpectedly over time. Genetic technologies offer versatile possibilities to design therapies against pathogens. Recent developments such as mRNA vaccines, CRISPR gene editing, and immunotherapies provide unprecedented hope to achieve significant results in the field of infectious diseases. This review will focus on advances in this domain, showcasing the cross-fertilization with other fields ( e.g., oncology), and addressing some of the logistical and economic concerns important to consider when making these advances accessible to diverse populations around the world.

UR - http://www.scopus.com/inward/record.url?scp=85171900921&partnerID=8YFLogxK

U2 - 10.1089/hum.2023.123

DO - 10.1089/hum.2023.123

M3 - Article

C2 - 37639360

SN - 1043-0342

VL - 34

SP - 896

EP - 904

JO - Human Gene Therapy

JF - Human Gene Therapy

IS - 17-18

ER -

Recent advances using genetic therapies against infectious diseases and for vaccination

Abstract

Bibliographical note

Access to Document

Handle.net

Other files and links

Fingerprint

EUAR135: BAXERNA 2.0 : Immunopeptidomics-based Development of Next-Generation Bacterial mRNA Vaccines

SRP84: SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell Therapy

Cite this

Recent advances using genetic therapies against infectious diseases and for vaccination

Abstract

Bibliographical note

Access to Document

Handle.net

Other files and links

Fingerprint

Projects

EUAR135: BAXERNA 2.0 : Immunopeptidomics-based Development of Next-Generation Bacterial mRNA Vaccines

SRP84: SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell Therapy

Cite this